219 related articles for article (PubMed ID: 29132013)
1. Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.
Li N; Liu S; Sun M; Chen W; Xu X; Zeng Z; Tang Y; Dong Y; Chang AH; Zhao Q
Transl Oncol; 2018 Feb; 11(1):11-17. PubMed ID: 29132013
[TBL] [Abstract][Full Text] [Related]
2. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma.
Shi H; Yu F; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Xu R; Jiang M; Shi J
J Thorac Dis; 2018 May; 10(5):2779-2788. PubMed ID: 29997940
[TBL] [Abstract][Full Text] [Related]
3. T cells redirected to EphA2 for the immunotherapy of glioblastoma.
Chow KK; Naik S; Kakarla S; Brawley VS; Shaffer DR; Yi Z; Rainusso N; Wu MF; Liu H; Kew Y; Grossman RG; Powell S; Lee D; Ahmed N; Gottschalk S
Mol Ther; 2013 Mar; 21(3):629-37. PubMed ID: 23070117
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.
Hsu K; Middlemiss S; Saletta F; Gottschalk S; McCowage GB; Kramer B
Cancer Gene Ther; 2021 Apr; 28(3-4):321-334. PubMed ID: 32873870
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
8. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
9. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
10. A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.
Muhammad N; Wang R; Li W; Zhang Z; Chang Y; Hu Y; Zhao J; Zheng X; Mao Q; Xia H
Mol Ther Oncolytics; 2022 Mar; 24():729-741. PubMed ID: 35317513
[TBL] [Abstract][Full Text] [Related]
11. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
12. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
13. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
14. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose.
Lin Q; Ba T; Ho J; Chen D; Cheng Y; Wang L; Xu G; Xu L; Zhou Y; Wei Y; Li J; Ling F
Front Oncol; 2021; 11():694941. PubMed ID: 34235085
[TBL] [Abstract][Full Text] [Related]
16. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
17. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
[TBL] [Abstract][Full Text] [Related]
19. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
20. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.
Wei X; Lai Y; Li J; Qin L; Xu Y; Zhao R; Li B; Lin S; Wang S; Wu Q; Liang Q; Peng M; Yu F; Li Y; Zhang X; Wu Y; Liu P; Pei D; Yao Y; Li P
Oncoimmunology; 2017; 6(3):e1284722. PubMed ID: 28405515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]